MedWatch

Ambu confirms preliminary figures for Q3 – operating profit drops below expectations

The medtech company had already downgraded its expectations for the full year earlier, publicizing some figures for the financial performance then, which have now been confirmed in the Q3 report.

Photo: Ambu/PR

Ambu has seen a setback on its bottom line in the third quarter of 2021/2022, according to the Danish medtech firm’s financial report, released on Thursday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs